Evidence review
Beta-sitosterol for prostate symptoms: evidence reviewed
A Cochrane review of four double-blind trials involving 519 men found that beta-sitosterol improved urinary symptom scores and urine flow compared with placebo over 4 to 26 weeks, without reducing prostate size. The findings are encouraging but old, short-term and based on few trials, and one trial using a pure glucoside preparation did not improve flow — so long-term effectiveness and the best preparation remain unknown.
Ingredient evidence ≠ product proof
This page reviews research on an ingredient. It does not show that any branded supplement containing that ingredient works, because commercial products may use a different form, dose or combination, and are rarely tested themselves. This is an evidence page: it contains no affiliate links.
The research question
Do beta-sitosterol preparations improve urinary symptoms and flow in men with benign prostatic hyperplasia compared with placebo?
Evidence table: population → dose → duration → result → limitations
| Study | Population | Dose / intervention | Duration | Result | Limitations |
|---|---|---|---|---|---|
| Cochrane review, 1999 | 4 double-blind RCTs; 519 men with BPH | Beta-sitosterol preparations (non-glucosidic mixtures and one pure glucoside) vs placebo | 4–26 weeks | IPSS about −4.9 points (2 trials); peak flow +3.9 mL/s (4 trials); residual volume −28.6 mL; no change in prostate size | Few, short trials; preparations differ |
| Glucoside-only trial (within Cochrane review) | Men with BPH | Pure beta-sitosterol glucoside (WA184) | Within 4–26 week range | No improvement in urinary flow | Single trial |
What the results show
The pooled estimates favour beta-sitosterol on both symptom score and objective flow measures, and withdrawal rates were similar to placebo (7.8% vs 8.0%). The Cochrane authors nonetheless flagged that long-term effectiveness, safety and the ability to prevent BPH complications were unknown. Because the evidence base has not been substantially updated with large modern trials, it cannot be weighed equally against saw palmetto’s larger, more recent negative trials. See our comparison of the two.
What the research does not prove
- That beta-sitosterol shrinks the prostate — prostate size did not change.
- That benefits persist beyond 26 weeks.
- That every “plant sterol” product matches the preparations tested.
- That combination prostate supplements work because they list beta-sitosterol.
Safety
- Well tolerated in trials, with withdrawal rates similar to placebo.
- Plant sterols are also used to lower cholesterol; people with the rare inherited condition sitosterolaemia should avoid sterol supplements.
- Urinary symptoms need medical assessment; supplements should not delay it.
Limitations of the evidence base
- Evidence largely predates modern trial reporting standards.
- Only four trials, with heterogeneous preparations.
- No long-term data on complications such as retention or surgery.
Frequently asked questions
Does beta-sitosterol help BPH?
Four short trials found improved symptom scores and flow compared with placebo; the evidence is old and limited.
Does it shrink the prostate?
No. Prostate size did not change in the Cochrane review.
Which form was studied?
Non-glucosidic beta-sitosterol mixtures improved flow; one pure glucoside preparation did not.
Related on FactoWiki
Beta-sitosterol ingredient guide · Saw palmetto evidence review · Prostate category
References
- Wilt T, Ishani A, MacDonald R, Stark G, Mulrow C, Lau J. Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev. 1999. PMID 10796740